Affimed lays off around 50 staffers as it brings combo NK cell therapy to PhII
23 May 2023
Cell Therapy
Affimed on Tuesday announced that it had laid off a quarter of its staff, or roughly 50 people, in April, joining a slew of other biotech companies that have let employees go over the past year.
The German NK cell biotech said the layoffs were needed to help fund three clinical programs that are currently in early-stage studies. “The bulk of the reductions have therefore come from other areas of the organization – discovery, preclinical, and some administrative roles,” an Affimed spokesperson told Endpoints News in an email.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 169,600+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.